Researcher and entrepreneur Sara Mangsbo has won the first prize for Entrepreneur of the Year in this year’s Super Talent competition. The Swedish magazine, Veckans affärer, awards Sweden’s 101 Super
Nordic Life Science
NLS News
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a
The company announces the addition of Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to its SAB and as Company Strategic Advisors.
Lena Söderström, who was previously in charge at Senzime, is the new chairman of the board of directors of the Umeå-based company Inficure Bio. Lena Söderström has worked in the
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the
The Norwegian cancer vaccine company has raised NOK 370 million and entered the Oslo Stock Exchange on Monday 3 June 2019. Several interested parties have now become shareholders in the
Drug & Device development
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the
The company has completed and announces positive results from the its Phase I/II clinical trial examining the safety and tolerability of the lead candidate, ilixadencel, in combination with tyrosine kinase
Findings presented from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza (liraglutide 1.8
Data from the company’s Phase 1/2 O-12-M1 clinical study of lead candidate melflufen demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated
The company has entered a non-binding term-sheet with STADA Arzneimittel for cooperation regarding sales and marketing of Spherotide for Europe, and furthermore, the company updates on its plans to take
Researcher and entrepreneur Sara Mangsbo has won the first prize for Entrepreneur of the Year in this year’s Super Talent competition. The Swedish magazine, Veckans affärer, awards Sweden’s 101 Super
Latest news
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the
The company has completed and announces positive results from the its Phase I/II clinical trial examining the safety and tolerability of the lead candidate, ilixadencel, in combination with tyrosine kinase
Findings presented from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza (liraglutide 1.8
Data from the company’s Phase 1/2 O-12-M1 clinical study of lead candidate melflufen demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated
The company has completed treatment of 25% of patients in the STAR trial of its medical device, SiPore15, and is well on track to finalize results by Q4 of this
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease. Data
The latest research news from the Nordic region
Science Article
The TEDDY study – which includes kids in Finland and Sweden – is finding factors that influence type 1 diabetes. Type 1 diabetes (T1D), which is often diagnosed in childhood,
The Nobel Prize is the most prestigious, most well-known and most reputable award in the entire world. Probably many factors lie behind its greatness; it has been awarded since 1901,
Scientists at Washington University School of Medicine and Umeå University have found a molecular compound that prevents and even reverses resistance to the most widely used antibiotic for treating tuberculosis
Radforsk, the Radium Hospital Research Foundation, is awarding several NOK 4.5 million to new research that fights cancer with light, reports Elisabeth Kirkeng Andersen, Oslo Cancer Cluster. Radforsk is an evergreen
We asked the new Minister about her goals and efforts when it comes to the country’s life science industry and Sweden’s status as an innovation and scientific research nation. How
The European Parliament has voted to end daylight saving time in EU member states. The biannual clock changes will come to an end in 2021 when individual member states will